VPodder's profile picture. Physician⏐ Postdoctoral Researcher ⏐ Author of First Aid for the USMLE Step 1 ⏐ Medical Editor ⏐ Patient Advocate

Vivek Podder, MBBS

@VPodder

Physician⏐ Postdoctoral Researcher ⏐ Author of First Aid for the USMLE Step 1 ⏐ Medical Editor ⏐ Patient Advocate

Vivek Podder, MBBS repostou

Now online: Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities doi.org/10.1158/1078-0…

CCR_AACR's tweet image. Now online: Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities doi.org/10.1158/1078-0…

Vivek Podder, MBBS repostou

Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. ja.ma/4ih8jV1

JAMAOnc's tweet image. Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. ja.ma/4ih8jV1

Vivek Podder, MBBS repostou

Join us for November Journal Club!  Wednesday, November 19th, 2025 11:00-11:45 CST (18:00-18:45 CET). November Lead Article for Discussion: Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy…

IGCSociety's tweet image. Join us for November Journal Club! 

Wednesday, November 19th, 2025 11:00-11:45 CST (18:00-18:45 CET).

November Lead Article for Discussion:
Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy…

Vivek Podder, MBBS repostou

✨ Don’t miss our next #IJGCclub! 🗓️ Nov 19 | 11:00 CDT (18:00 CEST) 📖 Checkpoint inhibitor rechallenge in advanced endometrial cancer with Brian M. Slomovitz, MD @GynCancerMD and Vivek Podder @VPodder (@SinaiHealth) 🔗 Don’t miss this engaging discussion:…

IJGConline's tweet image. ✨ Don’t miss our next #IJGCclub!
🗓️ Nov 19 | 11:00 CDT (18:00 CEST)
📖 Checkpoint inhibitor rechallenge in advanced endometrial cancer with Brian M. Slomovitz, MD @GynCancerMD and Vivek Podder @VPodder (@SinaiHealth)

🔗 Don’t miss this engaging discussion:…

Vivek Podder, MBBS repostou

Emerging Therapeutics in Low-Grade Serous Ovarian Carcinoma - @VPodder oncodaily.com/voices/vivek-p… #Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag

oncodaily's tweet image. Emerging Therapeutics in Low-Grade Serous Ovarian Carcinoma - @VPodder

oncodaily.com/voices/vivek-p…

#Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag

Vivek Podder, MBBS repostou

#LeadArticle Checkpoint inhibitor rechallenge in advanced #endometrialcancer: revisiting the immune landscape beyond first-line therapy ✅ bit.ly/48W0QIh @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert

IJGConline's tweet image. #LeadArticle Checkpoint inhibitor rechallenge in advanced #endometrialcancer: revisiting the immune landscape beyond first-line therapy

✅ bit.ly/48W0QIh

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert…

Vivek Podder, MBBS repostou

We just published in @TheLancetOncol a very important paper regarding the new FDA guidance on overall survival assessment in cancer drug trials. Right in time for #ESMO25. Please do read. I promise you that you’ll learn something that’s applicable broadly. And follow along this…

oncology_bg's tweet image. We just published in @TheLancetOncol a very important paper regarding the new FDA guidance on overall survival assessment in cancer drug trials. Right in time for #ESMO25. Please do read. I promise you that you’ll learn something that’s applicable broadly. And follow along this…

Vivek Podder, MBBS repostou

Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of #endometrialcancer 🧬 bit.ly/48K1s3N @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert

IJGConline's tweet image. Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of #endometrialcancer

🧬 bit.ly/48K1s3N

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert…

Vivek Podder, MBBS repostou

Onclive State of the Science Coming to Miami 10/30 Hosted by @OncLive @MountSinaiMiami Join us for a great way to learn and to network with friends and colleagues. So honored have this distinguished group of Key Opinion Leaders as speakers @DrKatyMoore @IJGConline @GOG

GynCancerMD's tweet image. Onclive State of the Science Coming to Miami 10/30
Hosted by @OncLive @MountSinaiMiami 
 Join us for a great way to learn and to network with friends and colleagues. So honored have this distinguished group of Key Opinion Leaders as speakers @DrKatyMoore @IJGConline @GOG

Vivek Podder, MBBS repostou

NEW: FDA releases draft guidance on overall survival assessment in oncology trials, with an emphasis on analyzing overall survival as a pre-specified safety endpoint. fda.gov/regulatory-inf…

FDAOncology's tweet image. NEW: FDA releases draft guidance on overall survival assessment in oncology trials, with an emphasis on analyzing overall survival as a pre-specified safety endpoint. fda.gov/regulatory-inf…

Vivek Podder, MBBS repostou

We need better treatments for our patients with advanced/metastatic cervix cancer!!! Open and accruing @MountSinaiMiami clinicaltrials.gov/study/NCT06459…

GynCancerMD's tweet image. We need better treatments for our patients with advanced/metastatic cervix cancer!!!
Open and accruing @MountSinaiMiami 

clinicaltrials.gov/study/NCT06459…

Vivek Podder, MBBS repostou

Honored to be a co-investigator on this practice changing trial. @GOG @MountSinaiMiami

Study shows relacorilant + nab-paclitaxel improves PFS and OS in patients with platinum-resistant ovarian cancer. Dr Brian Slomovitz (@GynCancerMD) shares that the data; safety profile may suggest a new standard for patients with PROC 👇 ecancer.org/en/video/12397… #ASCO25



Vivek Podder, MBBS repostou

telemundo51.com/noticias/local… Honored to be investigator using Tisotumab Vedotin @pfizer @Genmab that received @FDAOncology @US_FDA approval for women with cervical cancer. Grateful to @Telemundo for helping to raise cervical cancer awareness @igcs @IJGConline @GOG @MountSinaiMiami


Vivek Podder, MBBS repostou

#Editorial The challenge is no longer whether precision oncology can improve outcomes in #endometrialcancer but how rapidly and effectively these advancements can be integrated into standard clinical practice. 📌 bit.ly/4363lDa @pedroramirezMD @HsuMd @JayrajAarthi

IJGConline's tweet image. #Editorial The challenge is no longer whether precision oncology can improve outcomes in #endometrialcancer but how rapidly and effectively these advancements can be integrated into standard clinical practice.

📌 bit.ly/4363lDa

@pedroramirezMD @HsuMd @JayrajAarthi…

Excited to share our new @IJGConline editorial: “Precision oncology in endometrial cancer: closing the gap between potential and practice” w/ @GynCancerMD We explore genomics, racial disparities, immunotherapy, & access barriers. Read here: sciencedirect.com/science/articl…


Loading...

Something went wrong.


Something went wrong.